Want to see CELU full AI Analyst Report?
Top Page
Celularity
(NASDAQ:CELU)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▲(87.50% Upside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial performance (continued losses, recent revenue decline, negative equity) and negative corporate developments (Nasdaq compliance risks and signs of funding/leadership strain). Technicals provide some support via strong recent momentum, but the very high RSI indicates the move may be overextended, and valuation remains challenged due to negative earnings and no dividend.
Positive Factors
Allogeneic placental-cell platform
An off-the-shelf placental-cell platform could support repeatable manufacturing and broader therapeutic use than patient-specific approaches. Its applications across oncology and regenerative medicine provide multiple avenues for long-term pipeline development.
Negative Factors
Revenue contraction and persistent losses
Shrinking revenue alongside continuing operating and net losses shows that commercial traction has not yet translated into a scalable business. Persistent unprofitability limits internally funded development and increases dependence on future financing or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Allogeneic placental-cell platform
An off-the-shelf placental-cell platform could support repeatable manufacturing and broader therapeutic use than patient-specific approaches. Its applications across oncology and regenerative medicine provide multiple avenues for long-term pipeline development.
Read all positive factors
Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$48.63M
Dividend YieldN/A
Average Volume (3M)8.15M
Price to Earnings (P/E)―
Beta (1Y)3.14
Revenue Growth-51.03%
EPS Growth-35.20%
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume24,375,505
30 Day Avg. Volume8,153,673
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Celularity Business Overview & Revenue Model
Company Description
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious condi...
How the Company Makes Money
Celularity’s publicly described revenue model is based on (1) advancing its placental-derived allogeneic cell therapy pipeline toward commercialization and (2) monetizing its platforms through collaborations and other commercial arrangements. Spec...
Celularity Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.55M | 54.22M | 22.77M | 17.98M | 21.34M |
| Gross Profit | 20.19M | 39.23M | 6.75M | -1.69M | 11.68M |
| EBITDA | -77.66M | -43.71M | -183.95M | -138.83M | -88.11M |
| Net Income | -91.80M | -57.89M | -196.29M | 14.19M | -100.12M |
Balance Sheet | |||||
| Total Assets | 107.33M | 132.68M | 143.89M | 401.07M | 414.13M |
| Cash, Cash Equivalents and Short-Term Investments | 6.17M | 738.00K | 227.00K | 13.97M | 37.24M |
| Total Debt | 40.90M | 68.84M | 65.42M | 65.59M | 31.14M |
| Total Liabilities | 145.39M | 123.84M | 102.93M | 202.16M | 314.71M |
| Stockholders Equity | -38.06M | 8.84M | 40.96M | 198.90M | 99.42M |
Cash Flow | |||||
| Free Cash Flow | -13.25M | -6.56M | -42.73M | -143.11M | -116.30M |
| Operating Cash Flow | -13.25M | -6.40M | -38.69M | -137.88M | -110.10M |
| Investing Cash Flow | 0.00 | 514.00K | -4.05M | -5.24M | -5.90M |
| Financing Cash Flow | 18.65M | 6.70M | 24.09M | 119.84M | 98.56M |
Celularity Technical Analysis
Positive
0.80
Price Trends
0.90
Positive
0.90
Positive
1.14
Positive
Market Momentum
0.27
Negative
59.92
Neutral
51.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Positive. The current price of 0.8 is below the 20-day moving average (MA) of 1.17, below the 50-day MA of 0.90, and below the 200-day MA of 1.14, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 59.92 is Neutral, neither overbought nor oversold. The STOCH value of 51.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CELU.
Celularity Risk Analysis
Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celularity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $681.47M | -12.75 | -43.57% | ― | -66.63% | 57.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $12.05M | -0.29 | -536.78% | ― | ― | 22.10% | |
46 Neutral | $24.35M | -1.14 | -456.35% | ― | ― | 9.68% | |
44 Neutral | $48.63M | -0.42 | 411.46% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
CELU
Celularity
1.54
-0.81
-34.47%
LTRN
Lantern Pharma
1.84
-2.12
-53.54%
STTK
Shattuck Labs
6.50
4.75
271.43%
FBLG
FibroBiologics, Inc.
1.71
-9.16
-84.27%
Celularity Corporate Events
Business Operations and StrategyExecutive/Board Changes
Celularity Announces Sudden Exit of Chief Commercial Officer
Negative
Aug 7, 2026
On August 5, 2026, Celularity Inc. terminated the employment of Rick Gonzalez, who had been serving as the company’s Chief Commercial Officer, effective immediately. The abrupt departure of a key commercial executive may signal a shift in Ce...
Delistings and Listing ChangesRegulatory Filings and Compliance
Celularity Faces Nasdaq Listing Compliance Bid-Price Warning
Negative
Jul 29, 2026
On July 23, 2026, Celularity Inc. received notice from Nasdaq that its Class A common stock no longer meets the exchange’s minimum bid price requirement, after trading below $1.00 per share for 30 consecutive business days. The stock continu...
Executive/Board ChangesPrivate Placements and Financing
Celularity Secures Insider-Backed Short-Term Loan Facility
Negative
Jun 30, 2026
On June 29, 2026, Celularity entered into a secured $1 million short‑term loan agreement with the Philip Daniele Barach Family Trust, a related party lender affiliated with a significant shareholder, bearing 4.0% annual interest and maturin...
Business Operations and StrategyExecutive/Board Changes
Celularity Strengthens Leadership With New Executive Appointments
Positive
Jun 25, 2026
On June 19, 2026, Celularity’s board appointed entrepreneur and biotechnology-focused executive Steven N. Gordon as chief operating and administrative officer, elevating him from his prior role as EVP, Business Affairs and also naming him to...
Delistings and Listing ChangesRegulatory Filings and Compliance
Celularity Faces Nasdaq Listing Compliance Risk After Notice
Negative
Jun 12, 2026
On June 9, 2026, Celularity Inc. disclosed that it received a notice from Nasdaq stating that the company’s market value of listed securities had fallen below the $35 million minimum required for continued listing on the Nasdaq Capital Marke...
Business Operations and StrategyExecutive/Board Changes
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Positive
Jun 3, 2026
On May 29, 2026, Celularity appointed industry veteran Rick Gonzalez as Chief Commercial Officer to lead global commercial strategy for its placental-derived regenerative medicine portfolio, including cenplacel-L and the Lifebank cellular banking ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.